New Two-Part cancer drug enters first human tests
NCT ID NCT06959706
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and find the right dose, while also looking at how the drug moves through the body and whether it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TGW101 (a two-part drug: an antibody-drug conjugate and a chemical trigger)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 50 participants, focused mainly on safety. It is too soon to know if TGW101 will be effective, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
-
Honor Health
RECRUITINGScottsdale, Arizona, 85258, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
-
NEXT San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States